Imunon Inc Stock Cash And Equivalents
| IMNN Stock | USD 0.86 0.01 1.18% |
Imunon Inc fundamentals help investors to digest information that contributes to Imunon's financial success or failures. It also enables traders to predict the movement of Imunon Stock. The fundamental analysis module provides a way to measure Imunon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imunon stock.
Imunon | Cash And Equivalents |
Imunon Inc Company Cash And Equivalents Analysis
Imunon's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Imunon Cash And Equivalents | 42.11 M |
Most of Imunon's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imunon Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Imunon Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Imunon is extremely important. It helps to project a fair market value of Imunon Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Imunon's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Imunon's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Imunon's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Imunon Inc has 42.11 M in Cash And Equivalents. This is 94.87% lower than that of the Biotechnology sector and 90.58% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.44% higher than that of the company.
Imunon Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imunon's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imunon could also be used in its relative valuation, which is a method of valuing Imunon by comparing valuation metrics of similar companies.Imunon is currently under evaluation in cash and equivalents category among its peers.
Imunon Current Valuation Drivers
We derive many important indicators used in calculating different scores of Imunon from analyzing Imunon's financial statements. These drivers represent accounts that assess Imunon's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Imunon's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 24.8M | 37.3M | 22.7M | 9.6M | 6.2M | 5.8M | |
| Enterprise Value | 20.9M | 41.8M | 11.7M | 4.4M | 1.9M | 1.8M |
Imunon Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 3.34 M | ||||
| Shares Outstanding | 14.5 M | ||||
| Shares Owned By Insiders | 1.09 % | ||||
| Shares Owned By Institutions | 7.03 % | ||||
| Number Of Shares Shorted | 702.04 K | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 17.94 X | ||||
| Revenue | 125 K | ||||
| Gross Profit | 500 K | ||||
| EBITDA | (19.88 M) | ||||
| Net Income | (19.51 M) | ||||
| Cash And Equivalents | 42.11 M | ||||
| Cash Per Share | 5.93 X | ||||
| Total Debt | 1.62 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.52 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (19.02 M) | ||||
| Short Ratio | 3.42 X | ||||
| Earnings Per Share | (1.91) X | ||||
| Target Price | 13.2 | ||||
| Number Of Employees | 33 | ||||
| Beta | 2.13 | ||||
| Market Capitalization | 12.55 M | ||||
| Total Asset | 21.92 M | ||||
| Retained Earnings | (388.18 M) | ||||
| Working Capital | 10.85 M | ||||
| Net Asset | 21.92 M |
About Imunon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imunon Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imunon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imunon Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
Moving against Imunon Stock
| 0.75 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.73 | VCYT | Veracyte | PairCorr |
| 0.72 | VCEL | Vericel Corp Ord | PairCorr |
| 0.72 | VERA | Vera Therapeutics | PairCorr |
| 0.67 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Imunon Piotroski F Score and Imunon Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.